<DOC>
	<DOCNO>NCT02982057</DOCNO>
	<brief_summary>The aim present study compare evolution non culprit lesion treatment BVS versus optimal medical therapy 2-years follow-</brief_summary>
	<brief_title>Non Culprit Lesion Study</brief_title>
	<detailed_description>Objectives hypothesis : scaffolding non culprit /vulnerable coronary plaque BVS could facilitate stabilization process atherosclerotic plaque modification plaque morphology , especially lipid content consider one main factor lead recurrent MACE ACS . The interaction polymer Platform vessel wall , effect everolimus neointima growth cellular response medium could reduce inflammatory process vulnerable plaque could different Under OMT BVS implantation .</detailed_description>
	<criteria>STEMI multivessel ASCL Successful uneventful primary PCI Non culprit lesion &gt; /= 2.5mm RVD suitable investigation FFR At least one segment minimum 10 mm length contain non culprit lesion non compliant profile patient able sign IC cardiogenic shock leave main disease GFR &lt; 30ml/min/m2 previous CABG LVEF &lt; 35 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>